Literature DB >> 21430362

Use of intravenous etomidate to control acute psychosis induced by the hypercortisolaemia in severe paediatric Cushing's disease.

L F Chan1, M Vaidya, B Westphal, J Allgrove, L Martin, F Afshar, P C Hindmarsh, M O Savage, A B Grossman, H L Storr.   

Abstract

BACKGROUND: Psychosis secondary to paediatric Cushing's disease (CD) is extremely rare and presents a significant management challenge.
METHOD: We report a 14.7-year-old CD patient with acute psychosis and self-inflicted injuries following failed transsphenoidal pituitary surgery. Her mental state rapidly deteriorated precluding medical therapy.
RESULTS: Emergency intravenous low-dose etomidate infusion (3-3.5 mg/h) with dose titration according to the serum cortisol combined with a hydrocortisone infusion, in an intensive care setting, was effective in controlling the hypercortisolaemia. Her mental state improved with normalisation of her cortisol levels enabling oral administration of ketoconazole and bilateral adrenalectomy to be performed.
CONCLUSION: This case illustrates the safe and effective use of a low-dose etomidate infusion in an unusual case of paediatric CD.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430362     DOI: 10.1159/000324419

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  11 in total

Review 1.  The development of psychotic disorders in adolescence: a potential role for hormones.

Authors:  Hanan D Trotman; Carrie W Holtzman; Arthur T Ryan; Daniel I Shapiro; Allison N MacDonald; Sandra M Goulding; Joy L Brasfield; Elaine F Walker
Journal:  Horm Behav       Date:  2013-07       Impact factor: 3.587

Review 2.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Stress and neurodevelopmental processes in the emergence of psychosis.

Authors:  C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker
Journal:  Neuroscience       Date:  2013-01-05       Impact factor: 3.590

5.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 6.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

Review 7.  Pro/con debate: Is etomidate safe in hemodynamically unstable critically ill patients?

Authors:  Gordon Flynn; Yahya Shehabi
Journal:  Crit Care       Date:  2012-07-19       Impact factor: 9.097

Review 8.  Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Authors:  Andrea Pence; Megan McGrath; Stephanie L Lee; Douglas E Raines
Journal:  Ther Adv Endocrinol Metab       Date:  2022-02-14       Impact factor: 3.565

9.  Long-term outcomes of children treated for Cushing's disease: a single center experience.

Authors:  Galina Yordanova; Lee Martin; Farhad Afshar; Ian Sabin; Ghassan Alusi; Nicholas P Plowman; Fiona Riddoch; Jane Evanson; Matthew Matson; Ashley B Grossman; Scott A Akker; John P Monson; William M Drake; Martin O Savage; Helen L Storr
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

Review 10.  Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome.

Authors:  Rosario Ferrigno; Valeria Hasenmajer; Silvana Caiulo; Marianna Minnetti; Paola Mazzotta; Helen L Storr; Andrea M Isidori; Ashley B Grossman; Maria Cristina De Martino; Martin O Savage
Journal:  Rev Endocr Metab Disord       Date:  2021-01-30       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.